Rajat Thawani on “Combination Immunotherapy clinical trials in NSCLC”

Rajat Thawani, Assistant Professor, University of Chicago Hematology/Oncology, shared a post on X:

“It was an honor to present a talk on “Combination Immunotherapy clinical trials in NSCLC” at the Ontario Institute for Cancer Research for OICR Mondays.

In summary, I believe a good second line NSCLC option would be able to compete with anti PD-1/PD-L1 options.

Otherwise, we will be combining drugs to anti PD-1 agents (+/- chemotherapy) to improve ORR. We will have many options to choose from — dual checkpoints, ADCs, vaccines, cytokines and targeted therapies! How do we choose the best partner for the patient — Use AI for ‘precision immunotherapy?”

Radiological artificial intelligence – predicting personalized immunotherapy outcomes in lung cancer

Authors: Laila C. Roisman, Waleed Kian, Alaa Anoze, Vered Fuchs, Maria Spector, Roee Steiner, Levi Kassel, Gilad Rechnitzer, Iris Fried, Nir Peled and Naama R. Bogot.

Source: Rajat Thawani/X